Board of Directors

  • Tim Mayleben

    Tim Mayleben is President and Chief Executive Officer and has been a member of our board of directors since February 2010. Prior to joining Esperion, Tim was President, Chief Executive Officer and a Director at Vericel Corporation, formerly Aastrom Biosciences, Inc. Previously, Tim was President, Chief Operating Officer and a director of NightHawk Radiology Holdings, Inc. Prior to joining Nighthawk, Tim was the Chief Operating Officer of the original Esperion, until its acquisition by Pfizer in 2004. Tim is an advisor to, investor in, and member of the board of directors of several life science companies, including Kaléo Pharma, LOXO Oncology, Marinus Pharmaceuticals, and the Wolverine Venture Fund. Tim earned an MBA, with distinction, from the J.L. Kellogg Graduate School of Management at Northwestern University, and a BBA from the University of Michigan, Ross School of Business.

  • Jeffrey Berkowitz was appointed to our board of directors in November 2017. Jeffrey is the former executive vice president of Optum, Inc., a health services platform business of UnitedHealth Group, Inc. Previously, he was executive vice president and president of Pharma and Global Market Access with Walgreens Boots Alliance, Inc., a global pharmacy-led, health and well-being enterprise, where he was responsible for generic and branded procurement, specialty pharmacy, inventory management and oversaw relationships with pharmaceutical companies as well as pricing and reimbursement strategies with all payer segments. Additional experience includes serving as president of Walgreens Boots Alliance Development, GmbH, a joint venture between Walgreens Co. and Alliance Boots located in Switzerland; and having held a variety of senior executive positions with increasing responsibility in market access, sales and marketing with Merck and Schering-Plough as well as serving as healthcare attorney with Proskauer, LLP. Jeffrey earned his B.A. in political science from Union College in Schenectady, N.Y., and his J.D. from Brooklyn Law School in Brooklyn, N.Y.

  • Scott Braunstein, MD

    Scott Braunstein was appointed to our board of directors in June 2015. Scott is Chief Operating Officer at Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. Most recently, he served as a healthcare portfolio manager at Everpoint Asset Management. Previously, he spent 12 years with J.P. Morgan Asset Management as a healthcare analyst and managing director in the U.S. Equity team, and as a portfolio manager in the Global Healthcare team responsible for managing investments in pharmaceuticals, biotechnology, and medical devices. In 2010, Scott was appointed Chief Operating Officer of STAT Medical, where he is also a member of the board. From 2000 until 2002 he was in healthcare specialty sales at Deutsche Bank. Prior to that, Scott was Vice President of Operations at Defined Healthcare. Scott began his career as a practicing physician at the Summit Medical Group and as Assistant Clinical Professor at Albert Einstein College of Medicine and for Columbia University Medical Center after earning his medical degree from the Albert Einstein College of Medicine.

  • Dov Goldstein, MD

    Dov Goldstein has served on our board of directors since 2008. He most recently served as the Chief Financial Officer of Schrödinger Therapeutics. From 2014 to 2017 he was a Managing Partner at Aisling Capital, a private investment firm. From 2008 to 2014, he was a Partner at Aisling Capital. From 2006 to 2008, Dov was a Principal at Aisling Capital. He also served as Chief Financial Officer of Loxo Oncology (Nasdaq: LOXO).  From 2000 to 2005, Dov was Executive Vice President and Chief Financial Officer of Vicuron Pharmaceuticals, Inc. (Nasdaq: MICU) until its acquisition by Pfizer. Previously, he was Director of Venture Analysis at Healthcare Ventures. Dov is a director of a number of boards, including ADMA Biologics (Nasdaq: ADMA). Dov earned a BS in biology from Stanford University, an MD from the Yale School of Medicine, and an MBA from the Columbia Business School.

     

  • Antonio Gotto, Jr., MD, DPhil

    Antonio M. Gotto, Jr. was appointed to our board of directors in January 2014. Antonio is Co-Chairman of the Board of Overseers of the Joan and Sanford I. Weill Medical College of Cornell University and Vice President of Cornell University. From January 1997 to December 2011, he served as the Stephen and Suzanne Weiss Dean of the Joan and Sanford I. Weill Medical College of Cornell University and Provost for Medical Affairs of Cornell University. Previously, Antonio served as J.S. Abercrombie Chair of Atherosclerosis and Lipoprotein Research and Chairman and Professor of the Department of Medicine at Baylor College of Medicine and Methodist Hospital. Antonio currently serves as a member of the Institute of Medicine of the National Academy of Sciences and a Fellow of the American Academy of Arts and Sciences. He is also a past president of the International Atherosclerosis Society and a past president of the American Heart Association. He was a member of the Board of Directors of Aegerion Pharmaceuticals, Inc. until December 2, 2016, when it merged to form Novelion Therapeutics, Inc. (NASDAQ: NVLN). Antonio holds a BA degree from Vanderbilt University, a DPhil degree in Biochemistry from Oxford University in England, where he was a Rhodes Scholar, and an MD from Vanderbilt University School of Medicine. Antonio completed his residency training at Massachusetts General Hospital in Boston, Massachusetts.

  • Dan Janney

    Dan Janney has served as a member of our board of directors since November 2012. Dan is a managing director at Alta Partners, a life sciences venture capital firm, which he joined in 1996. Prior to joining Alta, Dan was a Vice President in Montgomery Securities’ healthcare and biotechnology investment banking group, focusing on life sciences companies. He is a director of a number of companies, including Alba Therapeutics Corporation, DiscoveRx Corporation, Lithera, Inc., Prolacta Bioscience, Inc. and ViroBay, Inc. Dan earned a BA in History from Georgetown University and an MBA from the Anderson School at the University of California, Los Angeles.

  • Mark McGovern, MD, FACC, FACP

    Mark E. McGovern was appointed to our board of directors in February 2014. Mark is a board-certified cardiologist with over 20 years of experience developing lipid regulating therapies. His experience includes 11 years at Bristol-Myers Squibb, where Mark was responsible for the clinical development of pravastatin (Pravachol®), in particular the programs for atherosclerosis regression and coronary heart disease prevention, including the WOSCOPS (West of Scotland Coronary Prevention Study), CARE (Cholesterol and Recurrent Events), and LIPID (Long-Term Intervention with Pravastatin in Ischaemic Disease) trials. He subsequently spent 10 years at Kos Pharmaceuticals, where he last served as Executive Vice President, Medical Affairs, and Chief Medical Officer. During his career at Kos, Mark oversaw the phase IV trials of extended-release niacin (Niaspan®), and the registration programs for the first combination lipid therapies, niacin extended-release/lovastatin (Advicor®) and niacin extended release/simvastatin (Simcor®). He currently serves as a consultant to the pharmaceutical industry for cardiovascular and atherosclerosis drug development. Mark earned his bachelor’s degree summa cum laude from Princeton University and his medical degree from the University of Vermont. Mark is a Fellow of the American College of Cardiology and the American College of Physicians. He has published extensively on lipid management and its role in the treatment of coronary heart disease.

  • Roger Newton, PhD, FAHA, FACN

    Roger Newton is Founder of Esperion and a member of our board of directors. Prior to founding Esperion in 2008, Roger was Senior Vice President, Pfizer Global R&D from 2004 to 2008. Previously, Roger was Co-Founder, President and CEO of the original Esperion from July 1998 until its acquisition by Pfizer in 2004. Prior to founding the original Esperion, Roger was Chairman of the Atherosclerosis Drug Discovery Team at Warner Lambert from 1981 to 1998. Roger is a fellow of the American Heart Association and director of a number of life science companies, including DeNovo Sciences and Juventas Therapeutics, Inc., and is also a member of the Technology Advisory Boards for Arboretum Ventures and Metagenics, Inc. Roger earned a PhD in Nutrition from the University of California, Davis, an MS in Nutritional Biochemistry from the University of Connecticut, and a BS in Biology from Lafayette College.

  • Nicole Vitullo

    Nicole Vitullo has served as a member of our board of directors since April 2008. Nicole joined Domain Associates, LLC, a venture capital firm with an exclusive focus on life sciences, in 1999, and became a Partner in 2004. From 1992-1999, Nicole was Senior Vice President at Rothschild Asset Management, Inc. Nicole is a director of a number of companies, including Celator Pharmaceuticals, Inc. (NASDAQ: CPXX), Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN), Durata Therapeutics, Inc. (NASDAQ: DRTX), Marinus Pharmaceuticals, Inc., and VentiRx Pharmaceuticals, Inc. Nicole earned a BA and an MBA from the University of Rochester.